This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, TAP-144-SR, Lucrin
Description: Leuprorelin (INN) is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, leuprolide initially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Takeda and Abbott
Takeda Pharmaceutical announced that it had reached an agreement on March 19, 2008, with Abbott Laboratories to evenly divide the value of their 50/50 joint venture TAP Pharmaceutical Products. Under terms of the agreement, Abbott receives rights to the oncology treatment, Lupron, including the commercial organization supporting that franchise, and will receive payments based on TAP's other current and certain future products. Takeda receives the rights to the product Prevacid, all the remaining TAP commercial and support organizations, and the rights to TAP's pipeline.
TAP was created in 1977 as a joint venture between Abbott and Takeda. In April 2008, TAP will be divided, and Abbott will obtain the rights to Lupron, all employees and assets primarily related to Lupron and others.
Takeda and Orion
Enanton (leuprolide acetate) is marketed by Orion in the Nordic countries under license from the Japanese company...See full deal structure in Biomedtracker
Partners: Orion Corporation Takeda Pharmaceutical Company Ltd
Pink Sheet TAP Lupron approvals and audits
Pink Sheet TAP Lupron Depot Infringement Case Stayed
Additional information available to subscribers only: